Amgen Inc. (NASDAQ:AMGN) Stock Holdings Increased by Captrust Financial Advisors

Captrust Financial Advisors raised its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 594,379 shares of the medical research company's stock after buying an additional 10,753 shares during the quarter. Captrust Financial Advisors owned approximately 0.11% of Amgen worth $154,919,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of AMGN. Centricity Wealth Management LLC acquired a new stake in shares of Amgen in the fourth quarter worth $25,000. Ritter Daniher Financial Advisory LLC DE increased its holdings in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares in the last quarter. Synergy Investment Management LLC purchased a new position in Amgen in the fourth quarter valued at about $34,000. Atala Financial Inc acquired a new position in shares of Amgen during the fourth quarter worth about $34,000. Finally, Heck Capital Advisors LLC purchased a new stake in shares of Amgen in the fourth quarter worth about $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Transactions at Amgen

In related news, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the transaction, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP David M. Reese sold 8,711 shares of the business's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the sale, the executive vice president now owns 62,147 shares in the company, valued at $18,222,743.34. This trade represents a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 67,752 shares of company stock worth $20,160,532. Company insiders own 0.69% of the company's stock.

Amgen Stock Performance

Shares of NASDAQ AMGN traded up $5.40 during mid-day trading on Wednesday, hitting $275.84. The company had a trading volume of 2,363,022 shares, compared to its average volume of 2,761,448. The stock has a market cap of $148.31 billion, a price-to-earnings ratio of 36.54, a PEG ratio of 2.63 and a beta of 0.51. The firm's 50 day simple moving average is $297.78 and its two-hundred day simple moving average is $290.54. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter in the previous year, the company posted $3.96 earnings per share. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.45%. Amgen's dividend payout ratio (DPR) is presently 86.86%.

Analyst Upgrades and Downgrades

Several research firms recently commented on AMGN. Mizuho boosted their price target on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday. Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Johnson Rice set a $294.00 price objective on shares of Amgen in a research report on Wednesday, March 5th. Finally, UBS Group reaffirmed a "neutral" rating and set a $315.00 target price (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $310.23.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.